InsidersTradesSigma
Track the vTv Therapeutics Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, vTv Therapeutics Inc. has recorded 15 reports. Market capitalisation: €129.6m. The latest transaction was disclosed on 25 September 2025 (Attribution). Among the most active insiders: PERELMAN RONALD O. Every trade is accessible without an account.
15
Insider Decl.
n/a
Thresholds
€37,768
8 ops.
Buy Volume
€88,984
3 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate vTv Therapeutics Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$54.33.
32Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 25 September 2025
Declarations15 total
106,000 shares@ US$15.26535.9% of flowClass A Common StockSEC:0001231919-25-000247:0
4,308 sharesCommon StockSEC:0000950170-25-113252:0
58,836 sharesClass A Common StockSEC:0001415889-24-028464:0
58,836 sharesClass A Common StockSEC:0001415889-24-028465:0
1,378 shares@ US$16.3528100.0% of flowClass A Common StockSEC:0001641489-24-000078:0
Canonical exit: 13 Feb 2025 (T+90)
4,776 shares0Common StockSEC:0000950170-24-028107:0
224,732 shares@ US$11.81100.0% of flowClass A Common StockSEC:0001415889-24-005996:0
20,539 shares@ US$0.8262100.0% of flowClass A common stockSEC:0000950142-22-003282:0
Canonical exit: 26 Feb 2023 (T+90)
87,000 shares@ US$1.150.056% mcap50.0% of flowClass A Common StockSEC:0000950142-21-004124:0
10,000 sharesClass A common stockSEC:0001567619-16-001835:0
Canonical exit: 12 May 2016 (T+90)
10,000 sharesClass A common stockSEC:0001140361-16-050484:0
Canonical exit: 5 May 2016 (T+90)
20,000 sharesClass A common stockSEC:0001140361-16-050332:0
Canonical exit: 4 May 2016 (T+90)
10,000 sharesClass A common stockSEC:0001140361-16-048197:0
Canonical exit: 14 Apr 2016 (T+90)
5,000 sharesClass A common stockSEC:0001567619-16-001675:0
Canonical exit: 11 Apr 2016 (T+90)
10,000 sharesClass A common stockSEC:0001567619-16-001675:1
Canonical exit: 12 Apr 2016 (T+90)
15 of 15 declarations
关于 vTv Therapeutics Inc.
vTv Therapeutics Inc. 是一家在美国上市的生物制药公司，在纳斯达克交易，股票代码为 VTVT。公司总部位于美国北卡罗来纳州海波因特，专注于发现和开发针对具有重大未满足医疗需求的慢性疾病的口服小分子候选药物。其商业模式是临床阶段开发商而非商业制药公司，这意味着投资案例主要由数据读数、监管里程碑和融资能力驱动，而非产品销售。（[vtvtherapeutics.com](https://vtvtherapeutics.com/about/?utm_source=openai)） 公司目前的战略围绕其主要临床资产 cadisegliatin 展开。vTv 将 cadisegliatin 描述为一种潜在的同类首创、口服、肝脏选择性葡萄糖激酶激活剂，正在研究作为 1 型糖尿病 (T1D) 患者胰岛素的辅助治疗。这种定位很重要：如果成功，口服附加疗法可以在一个仍然严重依赖注射胰岛素治疗方案的市场中提供差异化的方法。vTv 历史上也曾提及更广泛的研究组合，涵盖其他慢性病靶点和合作伙伴主导的项目，包括 2 型糖尿病和炎症性疾病等领域，尽管近期价值驱动因素仍是 T1D 项目。（[vtvtherapeutics.com](https://www.vtvtherapeutics.com/?utm_source=openai)） 从竞争角度来看，vTv Therapeutics 处于小型生物技术公司的高风险/高回报细分市场。该公司与规模更大、资金更充足的制药公司以及其他寻求糖尿病创新的临床阶段开发商竞争。其竞争差异化来自于其主要候选药物的口服小分子特性以及解决血糖控制方面未满足需求的潜力。与此同时，该公司尚未拥有广泛的商业足迹，因此其市场地位更多地由管线选择性而非收入规模或成熟产品系列定义。（[vtvtherapeutics.com](https://www.vtvtherapeutics.com/?utm_source=openai)） 近期发展对投资叙事至关重要。2025 年 3 月，vTv 报告称，FDA 于 2024 年 7 月对 cadisegliatin 施加的临床暂停已解除，这实质性地改善了该项目的轨迹。2025 年 2 月，该公司宣布与医疗保健机构投资者和 T1D 基金进行 80 million 美元的私募，增强了其资产负债表。最近，vTv 在 2025 年底发布了季度更新，并于 2026 年 5 月提交了其 10-Q 表格，强调执行、现金管理和即将到来的临床催化剂仍然是故事的核心。（[stocklight.com](https://stocklight.com/stocks/us/nasdaq-vtvt/vtv-therapeutics/annual-reports/nasdaq-vtvt-2025-10K-25756857.pdf?utm_source=openai)）
